Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 12Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid, Acute 7Blast Crisis 7Leukemia, Myeloid, Accelerated Phase 6Myeloproliferative Disorders 5Neoplasms by Histologic Type 4Neoplasms 4Leukemia, Myeloid 4Hematologic Diseases 4Bone Marrow Diseases 4Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Philadelphia Chromosome 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

blinatumomab 4fludarabine 3Rituximab 3Cyclophosphamide 3ponatinib 2ibrutinib 2fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Busulfan 2Bone Marrow Transplantation 2venetoclax 1tetulomab tetraxetan lu-177 1pomalidomide 1obinutuzumab 1durvalumab 1dacetuzumab 1amonafide 1acalabrutinib 1Tinzaparin 1Lutetium-177 1Lutetium 1Lenalidomide 1Imatinib Mesylate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphatic Diseases × ponatinib × Other hematologic neoplasm × Clear all
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡